Abstract : The safety and ef cacy pro les of alectinib versus crizotinib for patients with previously untreated anaplastic lymphoma kinase ALK -positive advanced non-small cell lung cancer still remains to be elucidated. We compared the overall ef cacies of alectinib and crizotinib for previously untreated ALK-positive advanced non-small cell lung cancer through a meta-analysis of randomized controlled trials. The primary outcome was progression-free survival PFS . Pooled estimates were calculated as hazard ratios with 95 confidence intervals. Two studies on alectinib met the inclusion criteria for this meta-analysis. The hazard ratio 95 con dence interval of alectinib for PFS, relative to crizotinib, was 0.41 0.28-0.60 , demonstrating a superior overall ef cacy of alectinib over crizotinib, in terms of PFS.
Introduction
Lung cancer is the most common cause of cancer-related death worldwide. Approximately 80 of lung cancer cases comprise non-small cell lung cancer NSCLC 1 . The 5-year survival rate for patients with lung cancer is only approximately 15 . Furthermore, patients with advanced NSCLC are generally considered to have a poor prognosis, with a median survival period of 8-10 months 1 2 .
Anaplastic lymphoma kinase ALK is a receptor tyrosine kinase belonging to the insulin receptor superfamily 3 4 . Various ALK gene alterations have been identi ed across a range of tumor types, including point mutations, deletions, and rearrangements. Numerous ALK fusions occur during cancer 4 . In particular, echinoderm microtubule-associated protein-like 4 EML4 -ALK, a fusion gene, occurs predominantly in NSCLC. In a study conducted in 2007, EML4-ALK was identi ed in patients with NSCLC and was de ned as a new molecular subset highly sensitive to ALK inhibition 3 .
The rst ALK inhibitor, crizotinib, was approved by the US Food and Drug Administration as a therapeutic option for NSCLC in 2011 and was rst used in Japan in 2012 5 . Since then, To whom corresponding should be addressed.
Original
ALK has been defined as a novel molecular target for NSCLC treatment. However, most patients experience disease progression less than a year after starting treatment with crizotinib, partially because crizotinib shows diminished therapeutic efficacy against various ALK point mutations, as well as metastasis to the central nervous system 5 .
Several second-generation ALK inhibitors are currently available as treatment options for NSCLC, and third-generation ALK inhibitors are under clinical investigation or at the preclinical research stage. Alectinib, a second-generation ALK inhibitor, has recently been approved in Japan for crizotinib-refractory ALK-rearranged NSCLC or advanced NSCLC 6 . A previous clinical study reported that alectinib is effective in most crizotinib-resistant ALK mutations, with a tolerable safety pro le 6 . Recently, large-scale randomized controlled trials RCTs of alectinib versus crizotinib treatment ef cacy have been completed and the results have revealed that alectinib is superior to crizotinib, in terms of progression-free survival PFS and safety pro le 7 8 . On this basis, alectinib is now expected to be the cornerstone of the rst-line treatment for patients with previously untreated ALK-positive advanced NSCLC 9 .
However, a meta-analysis to con rm the overall ef cacy and safety of alectinib compared with crizotinib is yet to be conducted. Therefore, relevant statistical data are needed to verify the overall ef cacy of alectinib compared to crizotinib in patients with previously untreated ALKpositive advanced NSCLC. In the present study, we aimed to statistically assess and compare the overall ef cacy pro les of alectinib and crizotinib via a meta-analysis of RCTs, and provide an explanation for the overall effect of alectinib versus crizotinib.
Materials and methods

Literature search
We searched the MEDLINE PubMed , Scopus, and Cochrane library databases for studies published up to July 2017 using the following terms : lung cancer, alectinib, and crizotinib . No restriction was imposed on the search language. Additional relevant articles were also searched in the reference lists of the retrieved articles. The electronic databases were independently searched by two investigators RM and KA . In the case of any discrepancies arising between the two investigators, a third investigator TO conducted additional evaluations or our research team resolved the discrepancy through discussions.
Inclusion and exclusion criteria
Studies were considered eligible if they met the following criteria : 1 studies should involve RCTs on the clinical ef cacy of alectinib versus that of crizotinib in patients diagnosed with previously untreated ALK-positive advanced NSCLC ; and 2 studies should include a PFS outcome. Observational, case-control, cohort, and non-blind clinical trials were excluded. All references were independently screened by KA and TO in accordance with the inclusion and exclusion criteria.
Data extraction
Relevant data from the eligible studies were extracted on the basis of the prede ned criteria for this meta-analysis. The primary outcome was PFS.
Assessment of the risk of bias
The Cochrane-recommended methodology 10 was employed to examine each of the selected studies for potential bias arising from random sequence generation ; allocation concealment ; blinding of participants or personnel and outcome assessment ; incomplete outcome data ; selective reporting ; and other factors.
Statistical analysis
Statistical heterogeneity among the trials was assessed using the I 2 statistic 11 , which measures the degree of heterogeneity in outcome measures by calculating the percentage of total variation among the included studies. I 2 values of ≥ 50 indicate signi cant heterogeneity. The signi cance of heterogeneity was tested using the 2 statistic. Random-effects models were developed, regardless of the presence or absence of statistically signi cant heterogeneity. The predefined primary and secondary outcomes of alectinib and crizotinib treatment were compared using the statistical method of inverse variance. Pooled estimates are presented as hazard ratios HRs with 95 confidence intervals. All analyses were performed using the RevMan software package version 5.3, Cochrane Corporation, Oxford, UK .
Results
Study characteristics
The study selection process is shown in Fig. 1 . We identi ed 66 manuscripts, of which 19 remained after removing duplicates. After title/abstract and full-text screening, two reports 7 8 , Fig. 1 . Study selection process including a total of 510 patients, were ultimately included in the present meta-analysis. The study characteristics are listed in Table 1 . The sample size ranged from 207 to 303 patients. The mean age ranged from 53.8 to 61.0 years. One study included only Japanese patients, whereas the other study included both Asian and non-Asian patients.
Bias assessment
On evaluating the selected studies for the risk of potential bias arising from random sequence generation, allocation concealment, blinding of participants or personnel and outcome assessment, incomplete outcome data, selective reporting, and other factors, we found that all the studies exhibited a low risk of bias for all factors. Figures 2A and 2B present the assessments performed by the authors of the present study for the risk of bias. No studies were excluded from this meta-analysis owing to poor quality or a difference in baseline characteristics.
Primary outcome
Two studies had comparatively assessed the difference in PFS between alectinib and crizotinib treatment. There was no signi cant inter-study heterogeneity among the studies that comparatively assessed overall survival after treatment with alectinib or crizotinib I 2 30 ; P 0.23 . A combined analysis of these comparisons was performed using a random-effects model. The results revealed that PFS was signi cantly longer for alectinib than for crizotinib, with an HR 95 con dence interval of alectinib relative to crizotinib of 0.41 0.28-0.60 .
Discussion
In this meta-analysis, we compared the ef cacy of alectinib treatment with that of conventional crizotinib treatment in patients with previously untreated ALK-positive advanced NSCLC. As expected, the results of the combined analysis revealed that patients who received alectinib exhibited a signi cantly greater PFS than those who received crizotinib.
Previous phase-3 studies compared the ef cacies of alectinib and crizotinib in patients with previously untreated ALK-positive advanced NSCLC 7 8 . These studies demonstrated the advanced NSCLC than crizotinib, with regard to PFS. To our knowledge, the present study is the rst meta-analysis assessing the overall ef cacy and safety of alectinib versus crizotinib in previously untreated ALK-positive advanced NSCLC. This combined meta-analysis of studies was essential to con rm the results of the previous phase-3 studies. We have previously demonstrated that alectinib is more effective and better tolerated than crizotinib, even in the general population. This combined analysis was meaningful from a clinical standpoint because the results reveal the overall effect size of the hazard ratio in patients with previously untreated advanced NSCLC treated with alectinib as opposed to those treated with crizotinib.
Several limitations of the present meta-analysis should be acknowledged. First, we only considered published studies, which might have contributed toward publication bias. Second, we used a random-effects model to account for the signi cant heterogeneity among the included studies, and data on heterogeneity could only be partially collected. Third, the drug dosages and frequency of administration varied among the studies included in the present meta-analysis, and this may have affected the nal conclusions. Fourth, the patients characteristics varied among the studies included in the present meta-analysis. Finally, the sample size in the present study was small : only 2 RCTs were analyzed. A meta-analysis of 2 studies is not uncommon, as seen in studies on orphan diseases. Nevertheless, issues addressed by these meta-analyses might be considered unresolved in the presence of heterogeneity. Fortunately, the present data did not exhibit any statistically signi cant heterogeneity.
In conclusion, the result of this combined meta-analysis comparing the treatment efficacies of alectinib and crizotinib showed that PFS was signi cantly greater in patients who received alectinib than in those who received crizotinib. Our results con rm the hypothesis that alectinib is more effective than crizotinib, with regard to PFS, in patients with previously untreated ALKpositive advanced NSCLC. However, there is an unmet medical need to identify subpopulations that might bene t from alectinib. Further detailed analyses are warranted to clarify the ef cacy and safety of alectinib for the treatment of previously untreated ALK-positive advanced NSCLC.
